Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.creatorMello Ayres Putinatti, Maria Stella de [UNESP]
dc.creatorLastoria, Joel Carlos [UNESP]
dc.creatorPadovani, Carlos Roberto [UNESP]
dc.date2014-12-03T13:07:02Z
dc.date2014-12-03T13:07:02Z
dc.date2014-03-01
dc.date.accessioned2023-09-09T09:34:32Z
dc.date.available2023-09-09T09:34:32Z
dc.identifierhttp://dx.doi.org/10.1590/abd1806-4841.20142037
dc.identifierAnais Brasileiros De Dermatologia. Rio De Janeiro Rj: Soc Brasileira Dermatologia, v. 89, n. 2, p. 266-272, 2014.
dc.identifier0365-0596
dc.identifierhttp://hdl.handle.net/11449/111183
dc.identifier10.1590/abd1806-4841.20142037
dc.identifierS0365-05962014000200266
dc.identifierWOS:000335171600009
dc.identifierS0365-05962014000200266.pdf
dc.identifier8727897080522289
dc.identifier9531498781164017
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8760866
dc.descriptionBACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL.
dc.descriptionUniv Estadual Paulista Julio de Mesquita Filho Un, Botucatu, SP, Brazil
dc.descriptionUniv Estadual Paulista Julio de Mesquita Filho Un, Botucatu, SP, Brazil
dc.format266-272
dc.languageeng
dc.publisherSoc Brasileira Dermatologia
dc.relationAnais Brasileiros de Dermatologia
dc.relation0.884
dc.relation0,520
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.subjectErythema nodosum
dc.subjectLeprosy
dc.subjectMedication therapy management
dc.subjectThalidomide
dc.titlePrevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
dc.typeArtigo


Este ítem pertenece a la siguiente institución